165 related articles for article (PubMed ID: 35598300)
1. Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population-based analysis.
Xu H; Han Y; Wu Y; Wang Y; Wang J; Xu B
Cancer Med; 2022 Dec; 11(23):4501-4512. PubMed ID: 35598300
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of microinvasive breast cancer across the different subtypes and human epidermal growth factor receptor 2 expression levels.
Lee SY; Yoo TK; Kim J; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Lee SB
Breast Cancer Res Treat; 2023 Jul; 200(1):47-61. PubMed ID: 37184775
[TBL] [Abstract][Full Text] [Related]
3. Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival.
Fan Y; Wang Y; He L; Imani S; Wen Q
ESMO Open; 2021 Aug; 6(4):100232. PubMed ID: 34392135
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes and a nomogram for de novo metastatic breast cancer with lung metastasis: a population-based study.
Liu W; Han Y
Sci Rep; 2022 Mar; 12(1):3597. PubMed ID: 35246585
[TBL] [Abstract][Full Text] [Related]
5. Risk and prognostic factors of breast cancer with liver metastases.
Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
Li X; Zhang X; Liu J; Shen Y
BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a prognostic nomogram for early HER2-positive and lymph node-negative breast cancer.
Shi Q; Wang J; Ai X; Xuhong J; Ma D; Zhang Y; Qi X; Jiang J
Gland Surg; 2021 Jul; 10(7):2255-2265. PubMed ID: 34422596
[TBL] [Abstract][Full Text] [Related]
8. Prognostic nomogram for patients with non-metastatic HER2 positive breast cancer in a prospective cohort.
Luo C; Zhong X; Wang Z; Wang Y; Wang Y; He P; Peng Q; Zheng H
Int J Biol Markers; 2019 Mar; 34(1):41-46. PubMed ID: 30852974
[TBL] [Abstract][Full Text] [Related]
9. The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study.
Han Y; Wu Y; Xu H; Wang J; Xu B
Int J Clin Oncol; 2022 Apr; 27(4):707-716. PubMed ID: 35041101
[TBL] [Abstract][Full Text] [Related]
10. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.
Chen XS; Ma CD; Wu JY; Yang WT; Lu HF; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
Tumori; 2010; 96(1):103-10. PubMed ID: 20437866
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
[TBL] [Abstract][Full Text] [Related]
12. The association between molecular type and prognosis of patients with stage IV breast cancer: an observational study based on SEER database.
Hou L; Qiu M; Chen M; Li F; Li J; Deng S; Yang Y; Du Z; Yang H
Gland Surg; 2021 Jun; 10(6):1889-1898. PubMed ID: 34268073
[TBL] [Abstract][Full Text] [Related]
13. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
14. Establishing a predicted model to evaluate prognosis for initially diagnosed metastatic Her2-positive breast cancer patients and exploring the benefit from local surgery.
Lin H; Wu Y; Liang G; Chen L
PLoS One; 2020; 15(11):e0242155. PubMed ID: 33170907
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Models Using Machine Learning Algorithms and Treatment Outcomes of Occult Breast Cancer Patients.
Qu J; Li C; Liu M; Wang Y; Feng Z; Li J; Wang W; Wu F; Zhang S; Zhao X
J Clin Med; 2023 Apr; 12(9):. PubMed ID: 37176539
[TBL] [Abstract][Full Text] [Related]
16. Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus.
Duan F; Song C; Ma Y; Jiang K; Xu F; Bi X; Huang J; Hong R; Huang Z; Lu Q; Yuan Z; Wang S; Xia W
Drug Des Devel Ther; 2021; 15():3463-3473. PubMed ID: 34408400
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
Hu G; Hu G; Zhang C; Lin X; Shan M; Yu Y; Lu Y; Niu R; Ye H; Wang C; Xu C
BMC Cancer; 2020 Feb; 20(1):136. PubMed ID: 32085753
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
[TBL] [Abstract][Full Text] [Related]
19. Association of molecular subtypes and treatment with survival in invasive micropapillary breast cancer: an analysis of the Surveillance, Epidemiology, and End Results database.
Tang Z; Li L; Huang X; Zhao Y; Huang L
Breast Cancer; 2024 Mar; 31(2):205-216. PubMed ID: 38043116
[TBL] [Abstract][Full Text] [Related]
20. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
Front Immunol; 2022; 13():947802. PubMed ID: 36405735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]